Utah Medical Products(UTMD)

Search documents
Utah Medical Products(UTMD) - 2024 Q4 - Annual Results
2025-01-28 20:22
Financial Performance - Revenues for 2024 decreased by 19% to $40.9 million compared to $50.2 million in 2023[4] - Net Income for 2024 was $9.2 million, a decline of 17% from $11.1 million in 2023[4] - Earnings Per Share (EPS) fell by 13% to $1.73 in 2024 from $1.99 in 2023[2] - In Q4 2024, total revenues were $9.2 million, down 25.8% from $12.3 million in Q4 2023[11] - The decline in annual revenues was primarily due to a $5.9 million (69%) drop in OEM sales to PendoTECH[17] - OUS distributor sales, excluding Filshie devices, decreased by $2.1 million (20%) in 2024[17] - Gross Profit (GP) for 2024 was $5,895 lower (19.6%) than in 2023, with a GP margin of 59.0% compared to 59.8% in 2023[24] - Operating Income (OI) decreased by $3,183 (19.0%) to $13,594 in 2024 compared to $16,777 in 2023[25] - Consolidated 2024 EBT was $16,802, representing 41.1% of sales, down from $20,089 (40.0% of sales) in 2023[33] - Adjusted consolidated EBITDA for 2024 was $19,852, a decrease from $26,635 in 2023, with a percentage of sales at 48.5% compared to 53.0% in 2023[35][36] - UTMD's non-US GAAP adjusted consolidated EBITDA for 2024 was $19,852 million, down 25.7% from $26,635 million in 2023[37] - Net Income for 2024 was $13,874 million, a decrease of 16.6% compared to $16,635 million in 2023, representing 33.9% of sales[38] - Diluted EPS for 2024 was $3.961, down 13.4% from $4.574 in 2023, with diluted shares decreasing from 3,637,071 to 3,503,165[39] Sales and Revenue Trends - The company expects a slight increase in sales from its China distributor for blood pressure monitoring kits in 2025[17] - UTMD projects higher OUS Filshie device sales in 2025 due to expected regulatory approvals[17] - OUS USD-denominated sales in 2024 were $17,458, a decrease of $4,562 (20.7%) compared to $22,020 in 2023[18] - Domestic U.S. sales in 2024 were $23,444, down $4,759 (16.9%) from $28,204 in 2023[21] - Sales invoiced in foreign currencies were $12,911, representing 74% of OUS sales and 32% of total consolidated sales[19] - The combined weighted-average favorable FX impact on 2024 foreign currency OUS sales was 0.3%, increasing reported USD sales by $113 compared to 2023[20] Shareholder Actions and Stock Performance - UTMD repurchased over 8% of its shares during the year, contributing to a stock price decline of 27%[2] - UTMD repurchased a total of 301,961 shares in 2024 at an average cost of $66.13 per share, totaling $19.968 million[44] - The number of outstanding shares at the end of 2024 was 3,335,156, down 8.1% from 3,629,525 at the end of 2023[40] - Dividends paid in 2024 totaled $4,260 million ($1.20 per share), slightly lower than $4,282 million ($1.18 per share) in 2023[43] Liquidity and Assets - Total cash and investments at the end of 2024 were $82.976 million, a decrease of $9.9 million from $92.868 million at the end of 2023[45] - The company's total assets decreased to $122.538 million at the end of 2024 from $135.458 million at the end of 2023[50] - The current ratio as of December 31, 2024, was 25.6, indicating strong liquidity[48] - The average inventory turns in 2024 were 1.8, reflecting inventory management efficiency[48] Future Outlook - Looking forward to 2025, UTMD expects total WW consolidated revenues to be lower again, in the low to mid-single percentage digits relative to 2024[23] - Litigation expenses in 2024 were $2,139 (5.2% of sales), up from $1,660 (3.3% of sales) in 2023[30]
Utah Medical Products: Favorably Skewed Risk/Reward Profile
Seeking Alpha· 2024-12-26 11:33
Group 1 - Utah Medical Products, Inc. (NASDAQ: UTMD) is facing negative market sentiment due to ongoing litigation related to its Filshie Clip product and a reduction in operational scale [1] - The company is perceived to be unfairly punished in the market despite its long-term potential [1] Group 2 - The article does not provide additional insights or data related to the broader industry or market trends [2][3]
Utah Medical Products(UTMD) - 2024 Q3 - Quarterly Report
2024-11-12 20:01
Financial Performance - Net sales for Q3 2024 were $10,005, a decrease of 20.0% compared to $12,505 in Q3 2023, and for the first nine months of 2024, net sales were $31,745, down 16.2% from $37,891 in the same period of 2023[27]. - Gross profit for Q3 2024 was $5,802, down 21.2% from $7,359 in Q3 2023, and for 9M 2024, gross profit was $18,820, a decrease of 18.0% from $22,940 in 9M 2023[27]. - Operating income for Q3 2024 was $3,343, down 15.8% from $3,969 in Q3 2023, and for 9M 2024, operating income was $10,664, a decrease of 16.9% from $12,833 in 9M 2023[27]. - Earnings per diluted share (EPS) for Q3 2024 were $1.025, down 5.2% from $1.081 in Q3 2023, and for 9M 2024, EPS were $3.098, a decrease of 8.7% from $3.394 in 9M 2023[27]. - Net income in Q3 2024 was $3,563 (35.6% of sales), a decrease of 9.4% from $3,935 (31.5% of sales) in Q3 2023; for 9M 2024, net income was $10,972 (34.6% of sales), down 11.1% from $12,349 (32.6% of sales) in 9M 2023[73]. Sales and Market Trends - Worldwide sales to the major OEM customer, PendoTECH, were $1,704 lower in Q3 2024 compared to Q3 2023, accounting for 73% of the lower year-to-date sales[27]. - Domestic U.S. sales in Q3 2024 were $5,687, a decrease of 21.7% from $7,265 in Q3 2023, with OEM sales down 54.7%[37]. - OUS sales in 9M 2024 decreased by 14.5% to $14,036 million compared to $16,424 million in 9M 2023, with a constant currency decline of 15.2%[44][45]. - In 3Q 2024, WW labor & delivery device sales were down 26%, and blood pressure monitoring and related OEM product sales decreased by 44% compared to 3Q 2023[48]. Profitability and Margins - The gross profit margin for Q3 2024 was 58.0%, slightly down from 58.8% in Q3 2023, while the operating income margin improved to 33.4% from 31.7% in the same period[29]. - Operating expenses as a percentage of sales were 24.6% in 3Q 2024, down from 27.1% in 3Q 2023, indicating improved cost management[54][60]. - Gross profit in 9M 2024 was $4,120 million lower (18.0%) compared to 9M 2023, but margins remained stable due to overhead adjustments[52]. - Consolidated EBT for Q3 2024 was $4,179 (41.8% of sales), down from $4,781 (38.2% of sales) in Q3 2023; for 9M 2024, EBT was $13,188 (41.5% of sales) compared to $15,072 (39.8% of sales) in 9M 2023[67]. Shareholder Returns - The company repurchased shares totaling $13,259 and paid $3,222 in dividends to stockholders during the first nine months of 2024[32]. - Dividends paid in Q3 2024 totaled $1,052 ($0.300/share), compared to $1,071 ($0.295/share) in Q3 2023; for 9M 2024, dividends were $3,222 ($0.300/share) versus $3,211 ($0.295/share) in 9M 2023[81]. - The company repurchased 58,377 shares for $3,866 in Q3 2024, at an average cost of $66.22/share; total shares repurchased in 9M 2024 were 196,592 for $13,259, averaging $67.45/share[79]. - UTMD returned $16,481 to stockholders in 9M 2024 through dividends and share repurchases, a substantial increase from $3,211 in 9M 2023[84]. Cash Flow and Investments - Net cash provided by operating activities in 9M 2024 was $11,894, down 29.9% from $16,949 in 9M 2023, primarily due to a $1,377 decrease in Net Income[82]. - Capital expenditures for property and equipment (PP&E) were $221 in 9M 2024, significantly lower than $549 in 9M 2023, indicating no expansion-related investments[83]. - The company plans to continue investing in new technology and processes, and remain open to acquisition opportunities to enhance revenue and EPS growth[86]. Future Outlook - The company expects a total annual consolidated sales decline of 18% to 19% in 2024 compared to 2023, with WW PendoTECH biopharmaceutical OEM sales projected to be $6 million lower[46]. - Management expects a revenue decline of 18 to 19% for the year 2024, along with a similar decline in Net Income[96]. Balance Sheet and Financial Ratios - Working capital decreased to $98,221 at September 30, 2024, from $101,559 at December 31, 2023, primarily due to a $4,416 decrease in cash[90]. - Total debt ratio improved to 4% as of September 30, 2024, down from 5% at December 31, 2023[92]. - UTMD's total consolidated assets decreased by $5,764 to $129,694 as of September 30, 2024, compared to December 31, 2023[87]. - Annualized ROE in 9M 2024 was 8%, down from 10% in 9M 2023; before dividends, it was 12% compared to 14% in the prior year[80].
Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales
ZACKS· 2024-10-30 17:16
Core Insights - Utah Medical Products, Inc. (UTMD) reported a decrease in earnings per share (EPS) to $1.025, down 5.2% from the previous year, with revenues dropping 20% year over year to $10 million [1][2] Revenue Performance - Worldwide consolidated sales decreased by 20%, with U.S. sales down 21.7% and international sales down 17.6% [3] - Domestic OEM sales experienced a significant decline of 54.7%, primarily due to a $1.1 million drop in PendoTECH sales, while direct Filshie Clip System sales fell by 10.7% [3] Profitability Metrics - Gross profit decreased by 21.2% to $5.8 million, with gross profit margin slightly contracting from 58.8% to 58% due to material cost inflation and lower operational efficiencies [4] - Operating income fell by 15.8% to $3.3 million, but the operating income margin improved from 31.7% to 33.4% due to reduced operating expenses [6] - Net income was reported at $3.6 million, a decrease of 9.4%, yet the net income margin improved from 31.5% to 35.6% [7] Operating Expenses - Operating expenses were reduced to $2.5 million, a 27.5% decrease from $3.4 million in the same quarter of the previous year, largely due to the end of amortization related to previous acquisitions [5] Non-Operating Income - Net non-operating income rose to $0.84 million from $0.81 million, supported by higher interest income and currency remeasurement gains, despite the impact of the U.S. excise tax on share repurchases [8] Balance Sheet Overview - As of September 30, 2024, cash and investments totaled $88.5 million, down from $92.9 million at the end of 2023, while total assets decreased to $129.7 million [9] - Current liabilities were reduced to $3.4 million, and stockholders' equity stood at $124.2 million, reflecting a minor decrease [9] Management Guidance - Management anticipates a $6 million annual revenue decline in 2024, primarily from reduced PendoTECH sales, projecting an overall revenue decline of around 18-19% year over year [10] - EBITDA is projected to range from $19 to $20 million for the full calendar year, indicating a focus on maintaining operational profitability [10] Share Repurchase Activity - During the third quarter, UTMD repurchased 58,377 shares at an average cost of $66.22 per share, totaling $3.9 million, reflecting management's confidence in the company's long-term value [11]
Utah Medical Products(UTMD) - 2024 Q3 - Quarterly Results
2024-10-29 18:47
Sales Performance - In Q3 2024, total worldwide consolidated sales were $2,500 (20.0%) lower than in Q3 2023, and for the first nine months (9M) of 2024, sales were $6,146 (16.2%) lower compared to 9M 2023[2][9]. - Domestic U.S. sales in Q3 2024 were $5,687, down 21.7% from $7,265 in Q3 2023, while for 9M 2024, domestic sales were $17,709, down 17.5% from $21,467 in 9M 2023[7][10]. - Sales to the major OEM customer, PendoTECH, were $1,704 lower in Q3 2024 and $4,483 lower in 9M 2024, accounting for 73% of the year-to-date sales decline[2]. - In 9M 2024, the company reported a 15.2% decline in OUS sales in constant currency terms compared to 9M 2023, with total consolidated sales expected to decline by 18% to 19% in 2024[12]. - Sales to OUS distributors/OEM customers were 8.5% lower in 9M 2024 compared to 9M 2023, indicating challenges in the distribution segment[12]. Profitability Metrics - Gross Profit (GP) margin in Q3 2024 was 58.0%, down from 58.8% in Q3 2023, while for 9M 2024, it was 59.3%, down from 60.5% in 9M 2023[3][4]. - Gross Profit (GP) in 9M 2024 was $4,120 (18.0%) lower than in 9M 2023, with GP margins remaining relatively stable due to overhead adjustments[13]. - Operating Income (OI) margin for Q3 2024 was 33.4%, compared to 31.7% in Q3 2023, and for 9M 2024, it was 41.8%, up from 39.8% in 9M 2023[3][5]. - Operating Income (OI) in 9M 2024 was $10,664, reflecting a decline of $2,169 (16.9%) compared to 9M 2023, primarily due to increased operating expenses[14]. - Total Operating Expenses (OE) in 9M 2024 were $8,156, representing 25.7% of sales, compared to $10,107 (26.7%) in 9M 2023[15]. Net Income and Earnings Per Share - Net Income (NI) in Q3 2024 decreased by 9% and by 11% in 9M 2024 compared to the respective periods in 2023[2]. - Net Income (NI) in 9M 2024 was $10,972, an 11.1% decrease from $12,349 in 9M 2023, with a net income margin of 34.6%[18]. - Earnings Per Share (EPS) in Q3 2024 were only 5% lower despite a 20% drop in revenues, and for 9M 2024, EPS were 9% lower with a 16% decline in revenues[5]. - Diluted Earnings per Share (EPS) in 9M 2024 were $3.098, down 8.7% from $3.394 in 9M 2023, with diluted shares decreasing to 3,477,797[19]. Expenses and Litigation - The company reported that ongoing litigation expenses related to Filshie product liability claims were 4.26% of revenues in Q3 2024, compared to 2.78% in Q3 2023[5]. - The company maintained S&M expenses in 9M 2024 at $1,395, a $186 increase from 9M 2023, primarily due to salary increases and additional sales personnel[15]. Cash Flow and Shareholder Returns - The company's cash and investments decreased by $4,416 to $88,452 as of September 30, 2024, primarily due to share repurchases and dividends[23]. - Total shares repurchased in 9M 2024 were 196,592 for $13,259, representing about 5.4% of shares outstanding at the end of 2023[22]. - The balance sheet remained strong with a higher current ratio and lower total liabilities despite lower sales and earnings, with $3,222 paid in dividends and $13,259 used for share repurchases in 9M 2024[5]. Market and Currency Impact - Foreign currency sales represented 35% of total worldwide consolidated Q3 2024 sales, with a favorable FX rate impact increasing reported USD sales by $96 compared to Q3 2023[2][8]. EBITDA and Future Expectations - Adjusted consolidated EBITDA for 3Q 2024 was $4,958, down 25% from $6,604 in 3Q 2023[20]. - Adjusted consolidated EBITDA as a percentage of sales was 49.6% in 3Q 2024, down from 52.8% in 3Q 2023[20]. - The company expects adjusted consolidated EBITDA for the entire 2024 calendar year to be in the range of $19 to $20 million[20]. - The company expects WW PendoTECH biopharmaceutical OEM sales to be $6 million lower in 2024 than in 2023, representing less than 7% of total consolidated sales[12]. Stock Performance - The closing share price at the end of 3Q 2024 was $66.91, a 20.6% decrease from $84.22 at the end of 2023[22].
Utah Medical Products(UTMD) - 2024 Q2 - Quarterly Report
2024-08-09 20:06
Financial Performance - Total consolidated net sales for 2Q 2024 were $10,400, a decrease of 19.2% compared to $12,866 in 2Q 2023, with 1H 2024 sales at $21,740, down 14.4% from $25,386 in 1H 2023[20]. - Gross profit for 2Q 2024 was $6,253, reflecting a 19.2% decline from $7,739 in 2Q 2023, while 1H 2024 gross profit was $13,018, down 16.4% from $15,581 in 1H 2023[20]. - The decline in sales was primarily attributed to three categories: WW PendoTECH OEM (70% of 2Q decline), China BPM Distributor (21%), and WW Filshie Clip System (16%) contributing to a total decline of $2,639[21]. - UTMD expects a total sales decline of $6 million for the year 2024 compared to 2023 due to reduced sales to its major biopharmaceutical OEM customer[22]. - The gross profit margin for 2Q 2024 remained stable at 60.1%, consistent with 2Q 2023, despite a 19% decrease in sales[22]. - Total consolidated sales in 1H 2024 were $3,646 (14.4%) lower than in 1H 2023, with biopharma pressure monitoring device sales to PendoTECH down $2,788 (57.5%)[33]. - WW consolidated Filshie sales in 1H 2024 were $918 (14.2%) lower than in 1H 2023, with domestic Filshie sales down $362 (14.8%)[34]. - OUS sales in 1H 2024 were $9,718, compared to $11,184 in 1H 2023, reflecting a decline of 13.1%[35]. - Gross Profit in 1H 2024 was $2,563 (16.4%) lower than in 1H 2023, with a Gross Profit Margin of 59.9% compared to 61.4% in 1H 2023[40]. - Operating Income in 2Q 2024 was $3,438, down $987 (22.3%) from $4,425 in 2Q 2023, maintaining a margin of 33.1%[42]. - Consolidated EBT for 2Q 2024 was $4,211 million, representing 40.5% of sales, compared to $5,172 million (40.2% of sales) in 2Q 2023[51]. - Net Income in 2Q 2024 was $3,453 million, a 17.8% decrease from $4,200 million in 2Q 2023, attributed to lower Operating Income[55]. - Diluted EPS in 2Q 2024 were $0.978, down 15.3% from $1.154 in 2Q 2023, reflecting a decrease in Net Income[57]. - Adjusted consolidated EBITDA for 1H 2024 was $10,489 million, a 24.6% decrease from $13,916 million in 1H 2023, primarily due to lower gross profit[52]. Sales and Market Trends - Total OUS sales in 2Q 2024 were $4,569, a decrease of 21.8% from $5,849 in 2Q 2023, with significant declines in sales to distributors in Ireland and China[30]. - Domestic Filshie sales in 2Q 2024 were $165 (13.9%) lower compared to 2Q 2023, indicating challenges in maintaining sales levels[28]. - Domestic U.S. sales in 2Q 2024 were $5,831, down from $7,017 in 2Q 2023, representing a decline of 16.9%[31]. - Direct non-Filshie device sales represented 63% of total domestic sales, remaining relatively stable with only a $8 (0.2%) decrease[31]. - Domestic OEM sales were $1,013 (47.0%) lower, primarily due to a $1,124 decline in U.S. PendoTECH sales[31]. - The company projects 2024 sales to be 20-22% lower than in 2023 due to ongoing weakness in Filshie device sales and lack of orders from its largest OEM customer[38]. Expenses and Investments - Total Operating Expenses in 1H 2024 were $5,697, down from $6,717 in 1H 2023, with S&M expenses increasing to 4.4% of sales[43]. - Total consolidated G&A Operating Expenses in 2Q 2024 were $2,014 million, a decrease of $761 million compared to the same period in 2023[45]. - R&D expenses in 2Q 2024 were $255 million, significantly higher than $133 million in 2Q 2023, due to extensive validation studies required by biopharmaceutical manufacturers[46]. - The total cost of share repurchases in 1H 2024 was $9,393 million, with 138,215 shares repurchased at an average price of $67.96[59]. - Capital expenditures for property, plant, and equipment (PP&E) were $132 in 1H 2024, a decrease of 63.6% from $363 in 1H 2023[63]. Cash Flow and Financial Position - Ending cash and investments as of June 30, 2024, were $89.2 million, down from $92.9 million at the end of 2023, after paying $2.2 million in dividends and repurchasing $9.4 million of common stock[23]. - Net cash provided by operating activities in 1H 2024 was $8,038, down 32.5% from $11,828 in 1H 2023, primarily due to a $1,005 decrease in Net Income[62]. - Working capital was $98,383 at June 30, 2024, down from $101,559 at December 31, 2023, with cash balances comprising 91% of working capital[70]. - Total liabilities decreased by $1,165 to $5,980 as of June 30, 2024, with a total debt ratio of 4.6%[71]. - Total consolidated assets decreased by $5,425 to $130,032 as of June 30, 2024, compared to December 31, 2023[67]. Management and Future Outlook - UTMD's current backlog for WW PendoTECH shipments is approximately $450, with minimal new orders expected for the second half of 2024[26]. - Management plans to introduce high-pressure process control transducer configurations to biopharmaceutical manufacturers and continue product development in 2H 2024[72]. - EPS is expected to benefit from share repurchases, despite lower than projected revenues for the year[73]. - The average age of trade receivables was 32 days at June 30, 2024, compared to 24 days at December 31, 2023, indicating strong collection performance[66]. - UTMD's cash and investments decreased by $3,650 to $89,219, primarily due to cash used for stock repurchases and dividends[66].
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales
ZACKS· 2024-07-26 18:46
Core Insights - Utah Medical Products Inc. (UTMD) reported a second-quarter 2024 earnings per share (EPS) of $0.98, a 15.3% decrease from $1.15 in the second quarter of 2023 [1] - The company experienced a notable decline in revenues and profits, primarily driven by significant reductions in sales to major customers and distributors, while maintaining healthy profit margins and continuing investments in share repurchases and dividends [2] Revenue Breakdown - Sales to UTMD's largest blood pressure monitoring (BPM) kit distributor in China were 39.3% lower in the second quarter of 2024 compared to the same quarter in 2023 [3] - Domestic sales were $5.8 million in the second quarter of 2024, a 16.9% decline from $7 million in the year-ago quarter [5] - Total revenues for the quarter stood at $10.4 million, a 19.2% decrease from $12.9 million in the second quarter of 2023 [10] - International sales were $4.6 million in the reported quarter, down 21.9% from $5.9 million in the year-ago quarter [13] Financial Performance - Gross profit for the second quarter of 2024 was $6.3 million, a 19.2% decrease from $7.7 million in the second quarter of 2023, with a gross profit margin of 60.1% [6] - Operating income was $3.4 million, down 22.3% from $4.4 million in the prior year quarter, with an operating income margin of 33.1% [6] - Income before tax (EBT) for the reported quarter was $4.2 million, an 18.6% decline from $5.2 million in the year-ago quarter, while net income was $3.5 million, down 17.8% from $4.2 million a year ago [15] Operating Expenses - Total operating expenses in the reported quarter were $2.8 million, a 15% decrease from $3.3 million a year ago [7] - Sales and Marketing (S&M) expenses increased to $0.5 million from $0.4 million in the year-ago quarter, while General and Administrative (G&A) costs decreased to $2 million from $2.8 million [14] Balance Sheet and Shareholder Returns - Total stockholders' equity was $124.1 million as of June 30, 2024, compared with $128.3 million at the end of December 2023, with a current ratio improving to 26.0 from 22.6 [8] - Cash and investments totaled $89.2 million, down from $92.9 million at the end of December 2023, with total assets at $130 million [16] - The company repurchased 95,107 shares at an average price of $67.33 per share and paid $1.1 million in dividends to stockholders during the second quarter of 2024 [17]
Zacks Initiates Coverage of UTMD With Neutral Recommendation
zacks.com· 2024-05-28 14:16
Company Overview - Utah Medical Products, Inc. (UTMD) has been initiated with a Neutral recommendation, highlighting its strong positioning in the medical device market while acknowledging challenges such as intense competition and the loss of a major OEM customer [1] - The company operates in the expanding medical device industry, driven by increasing chronic disease prevalence, an aging population, and rising demand for home healthcare [2] Financial Performance - In the first quarter of 2024, UTMD's international sales accounted for 45.4% of total revenues, indicating a well-diversified revenue stream and exposure to growth opportunities in emerging markets [3] - Despite increased litigation costs, UTMD improved its net income margin to 34.9% in Q1 2024 from 33.7% in Q1 2023, reflecting strong cost management [4] - The company reported a significant reduction in general and administrative expenses by 23.3% in Q1 2024 compared to Q1 2023 [4] - As of March 31, 2024, UTMD had $93.8 million in cash and investments, providing financial flexibility and stability due to the absence of debt [5] Shareholder Returns - UTMD has consistently returned value to shareholders through stock repurchases and cash dividends, repurchasing 43,108 shares and paying $1.1 million in cash dividends in Q1 2024 [6] Challenges - The termination of a significant OEM customer relationship led to a 9.4% sales decline in Q1 2024, with expectations of further revenue losses throughout 2024 due to the absence of new orders from this customer [7] - The company experienced a decline in both net sales and gross profit margins in Q1 2024, attributed to lower absorption of manufacturing overhead costs [8] - UTMD faces intense competition from industry giants, which may lead to pricing pressures and reduced margins [8] Market Position - UTMD's share price has declined significantly over the past year, reflecting investor concerns over recent challenges, despite trading at a discount compared to its peer group [9] - The current trading multiples suggest that while UTMD has recovery potential, its valuation remains constrained by uncertainties impacting future performance [9] Conclusion - While UTMD is well-positioned in a growing market with a strong product portfolio and solid financials, it faces significant hurdles that could impact future performance [10]
Utah Medical Products(UTMD) - 2024 Q1 - Quarterly Report
2024-05-10 15:18
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC (Exact name of Registrant as specified in its charter) Utah 87-0342734 (State or other jurisdiction of incorpo ...
Utah Medical Products(UTMD) - 2023 Q4 - Annual Report
2024-03-26 15:57
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-12575 UTAH MEDICAL PRODUCTS INC (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organizatio ...